Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
721-740 of 3,900 trials

HER2-Positive Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan Study

We are investigating a new treatment combining Trastuzumab Deruxtecan with immunotherapy and chemotherapy for patients with advanced HER2 over-expressing Non-Small Cell Lung Cancer. The study aims to evaluate the safety and tolerability of this approach.

HER2 Positive Non-Small Cell Lung Cancer>2 yearsSafety phase (I)Oncology

HIV and Liver Health: Doravirine Study

We are exploring how the medication Doravirine affects liver fat and fibrosis in people living with HIV who have liver issues. This study aims to see if switching to Doravirine improves liver health over time.

Human Immunodeficiency Virus (HIV)1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesHepatologyInfectious DiseasesInternal Medicine

Triple-Negative Breast Cancer: MK-2870 with Pembrolizumab

We are studying a new treatment combining MK-2870 and pembrolizumab for people with triple-negative breast cancer who had surgery but did not respond completely. The trial aims to see if this combination works better than standard treatment options.

Triple Negative Breast Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Cervical Cancer: Surgery Plus Therapy Study

We are investigating whether additional therapy after surgery helps patients with early-stage, intermediate-risk cervical cancer stay cancer-free. This study compares outcomes with and without further treatment.

Early-Stage Cervical Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Advanced Solid Tumors: AZD9574 Treatment Study

We are studying the safety and early effectiveness of AZD9574, both alone and with other cancer therapies, for patients with advanced solid tumors. This research aims to improve treatment options for those facing these challenging conditions.

Advanced Ovarian, Breast, Pancreatic, or Prostate CancerHER2+ Metastatic Solid TumorsAdvanced Unresectable or Metastatic Solid TumorsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Surgical Site Infection Prevention: Linezolid vs. Vancomycin

We are studying whether linezolid is as effective as vancomycin in preventing infections after surgery. This trial includes various surgeries and looks at infection rates and patient experiences.

Surgical Antibiotic Prophylaxis>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesOrthopedics and Traumatology

Advanced Breast Cancer: Capivasertib with CDK4/6 Inhibitors

We are studying a new treatment combining capivasertib with CDK4/6 inhibitors and fulvestrant for patients with advanced hormone receptor-positive, HER2-negative breast cancer. The goal is to see if this combination improves treatment outcomes compared to standard therapies.

Hormone Receptor-Positive and HER2-Negative Breast Cancer3-6 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Acute Myeloid Leukemia: CHIP-AML22 Trial

We are studying new treatment options for children and adolescents with newly diagnosed AML to see if they improve survival and reduce side effects compared to standard therapies.

Acute Myeloid Leukemia6-12 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesHematologyPediatrics

Quizartinib for Pediatric FLT3-ITD Positive AML

We are studying the safety and effectiveness of quizartinib combined with chemotherapy in children and adolescents newly diagnosed with FLT3-ITD positive acute myeloid leukemia. This trial aims to see if it helps improve treatment outcomes compared to standard therapies.

Pediatric Acute Myeloid Leukemia (AML)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Prostate Cancer: New Treatment Combining Radiation and Antiandrogen

We are studying a new treatment approach for men with advanced prostate cancer to see if combining radiation therapy with a second-generation antiandrogen improves outcomes. The trial will also look at quality of life and any side effects from the treatment.

Oligometastatic Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

Colchicine for Heart Health After PCI

We are studying whether colchicine can help reduce serious heart events in patients with coronary artery disease after a heart procedure. This trial compares colchicine to a placebo to see its effects on heart health.

Coronary Artery DiseaseConfirmation phase (III)6-10 visitsStandard MedicinesCardiologyInternal Medicine

HER2-Positive Oligo-Metastatic Breast Cancer: T-DXd Treatment Study

We are investigating how well T-DXd works in combination with other treatments for patients with HER2-positive oligo-metastatic breast cancer. The study will also look at safety and how it affects cancer markers in the blood.

HER2-Positive Metastatic Breast Cancer6-12 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Non-Seminomatous Germ-Cell Tumors: Personalized Treatment Study

We are exploring new treatment strategies for young adults with poor-prognosis non-seminomatous germ-cell tumors. This study aims to improve outcomes through personalized care and early assessments.

Germ Cell Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

Long-Term Study of Delandistrogene Moxeparvovec (SRP-9001)

We are assessing the long-term safety and effectiveness of delandistrogene moxeparvovec in individuals who previously participated in a clinical study. This research aims to understand how the treatment continues to affect participants over time.

Duchenne Muscular Dystrophy>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyOrthopedics and Traumatology

Spironolactone for Arrhythmogenic Right Ventricular Dysplasia (ARVD)

We are studying whether spironolactone can help reduce heart deterioration and arrhythmias in patients with ARVD. This trial compares its effects to a placebo over one and three years.

Arrhythmogenic Right Ventricular Dysplasia>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesCardiologyInternal Medicine

Multiple Myeloma: HyQvia for Infection Prevention

We are studying whether HyQvia can help reduce infections in patients with newly diagnosed multiple myeloma who are not eligible for a transplant. The trial aims to see if it improves survival and quality of life compared to standard care.

Multiple Myeloma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyInfectious Diseases

Lung Cancer Treatment Comparison: Atezolizumab vs. Pembrolizumab

We are studying two treatment combinations for patients with metastatic TTF-1 negative lung adenocarcinoma to see which one may improve survival. This trial compares atezolizumab with carboplatin and nab-paclitaxel against pembrolizumab with platinum and pemetrexed.

Metastatic Lung Adenocarcinoma>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOncologyPulmonology

Juvenile Idiopathic Arthritis: Upadacitinib Study

We are evaluating the safety and how the body processes upadacitinib in children with polyarticular course juvenile idiopathic arthritis. The study also examines how well children tolerate the medication and its taste.

Juvenile Idiopathic Arthritis>2 yearsSafety phase (I)Post-Trial Drug AccessNo PlaceboStandard MedicinesPediatricsRheumatology

Advanced Solid Tumors: Amivantamab Treatment Study

We are studying a new treatment called amivantamab for patients with advanced or metastatic solid tumors, including those with EGFR-mutated lung cancer. The goal is to see how well it works when combined with other therapies.

Non-small Cell Lung CancerEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Advanced Non-Squamous NSCLC: Dato-DXd with Rilvegostomig

We are studying if a new treatment combination is safe and effective compared to pembrolizumab for patients with advanced non-squamous lung cancer. This trial is for those with high PD-L1 levels and no specific genetic changes.

Non-Small Cell Lung CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology